Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
184M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
122M
-
Shares change
-
-8.09M
-
Total reported value, excl. options
-
$242M
-
Value change
-
-$29.2M
-
Put/Call ratio
-
1.18
-
Number of buys
-
84
-
Number of sells
-
-74
-
Price
-
$1.99
Significant Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) as of Q3 2024
212 filings reported holding HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock as of Q3 2024.
HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
of 184M outstanding shares and own 66.38% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (26.7M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (8.85M shares), VANGUARD GROUP INC (8.72M shares), BlackRock, Inc. (8.53M shares), Velan Capital Investment Management LP (6.99M shares), Tejara Capital Ltd (5.31M shares), D. E. Shaw & Co., Inc. (4.38M shares), PALISADE CAPITAL MANAGEMENT, LP (3.99M shares), STATE STREET CORP (3.19M shares), and GEODE CAPITAL MANAGEMENT, LLC (3.05M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.